Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (303)	10/18/2000 8:58:03 PM
From: Miljenko Zuanic	Respond to of 523

Thanks. I think that it was good for NRGN when he retired as CEO (and went to BS somewhere else). quote: <<Penner said in a statement that he has done "what he came here to do.">> No comment! Miljenko [eom]

To: Jim Oravetz who wrote (303)	11/13/2000 12:27:07 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 523

Neurogen Corp. - Branford, Conn. 3rd Quar Sept. 30: 2000 1999 Revenue $7,250,000 $2,630,000 Net income a 697,000 (3,665,000) Avg shrs (basic) 17,277,000 b 14,588,000 Avg shrs (diluted) 18,872,000 b 14,588,000 Shr earns (basic) Net income a .04 b (.25) Shr earns (diluted) Net income a .04 b (.25) Figures in parentheses are losses. a. Includes $4.9 million in fees from Pfizer Inc. relating to a June 1999 licensing agreement. b. Excludes contingently issuable common stock securities because they are anti-dilutive.